What is Soleno Therapeutics's latest dividend and current dividend yield?

What is Soleno Therapeutics's gross profit margin?

What does Soleno Therapeutics do and what are its main business segments?

What were the key takeaways from Soleno Therapeutics's earnings call?

What were the key takeaways from Soleno Therapeutics’s earnings call?

What is the market's earnings forecast for Soleno Therapeutics next quarter?

What factors drove the changes in Soleno Therapeutics's revenue and profit?

What is the revenue and EPS growth rate for Soleno Therapeutics year over year?

- **Revenue & Profitability**: Q4 2025 revenue $91.7M, full year $190.4M; net income $20.9M for 2025.
- **Market Penetration**: 1,250 patient starts (12.5% of U.S. market), 859 active patients.
- **New Indications**: Glycogen storage disease type 1 IND filing, targeting 2026 trial.
- **EU Progress**: MAA submission for PWS, mid-2026 approval expected.
- **Financial Strength**: $506M cash, transitioning to at-cost inventory.

**【CEO Summary Section】**
- Total net revenue for Q4 2025: $91.7 million, full year 2025: $190.4 million.
- Achieved profitability with net income of $20.9 million for the year.
- Generated $48.7 million in cash from operating activities, ending with $506.1 million in cash.
- 1,250 patient start forms submitted (12.5% of U.S. addressable market), 859 active patients as of Q4.
- Discontinuation rate due to adverse events: 12%, long-term expectation 15%-20%.
- EU MAA submission for VYKAT XR in PWS, targeting mid-2026 approval.

**【CFO Financial Commentary】**
- Q4 2025 net income: $43.4 million ($0.82 per share), full year 2025: $20.9 million ($0.40 per share).
- Research & development expenses: $40.6 million for 2025, down 48% YoY.
- Selling, general & administrative expenses: $132.1 million for 2025, up 25% YoY.
- Launched accelerated share repurchase program, investing $100 million in shares.
- Transitioning from zero-cost inventory to at-cost inventory, impacting COGS.

**【Q&A Highlights】**
- **Patient Start Forms Cadence**: Guided to 1,000 new starts over 9-12 months, no seasonal bolus expected.
- **EU Regulatory Update**: Day 180 questions expected by end-February, targeting mid-2026 approval.
- **GSD1 Expansion**: Filed IND for glycogen storage disease type 1, targeting 2026 clinical trial.
- **Discontinuation Rate**: 12% AE-related, 15% total; long-term expectation 15%-20%.
- **COGS Impact**: Full-cost inventory will increase COGS as zero-cost inventory depletes.
- **EU Launch Strategy**: Evaluating self-launch vs. partner, focusing on Germany/Austria centers of excellence.


Soleno Therapeutics, Inc. (SLNO) Q4 2025 Earnings Call Transcript

- **Revenue milestone**: Q3 2025 net revenue doubles to $66 million, marking first profitable quarter.
- **Market adoption**: 764 active patients on VYKAT XR, 494 prescribers, and 132 million lives covered by payers.
- **Discontinuation management**: 8% AE-related discontinuations, with efforts to restart therapy through patient education.
- **Global expansion**: EU regulatory progress for 9,500 PWS patients, despite ongoing U.S. launch.
- **Financial strength**: $556 million cash balance supports commercialization and international expansion.

**【CEO Summary Section】**
- Total net revenue doubled to $66 million in Q3 2025, achieving profitability with a net income of $26 million.
- VYKAT XR launch momentum continued despite a mid-August short seller report causing temporary disruption in patient start forms and discontinuations.
- 764 active patients on therapy at quarter-end, with 1,043 cumulative patient start forms and 494 unique prescribers.
- Discontinuation rate due to adverse events (AEs) was 8%, below long-term expectations, with most AEs being nonserious (e.g., edema, hyperglycemia).
- EU regulatory progress: EMA Day 120 questions received, similar to FDA discussions, with potential market expansion for 9,500 PWS patients in key European countries.

**【CFO Financial Commentary】**
- Q3 2025 revenue: $66.0 million (vs. $32.7 million in Q2 2025), net income: $26.0 million (vs. -$76.6 million in Q3 2024).
- Cash from operations: $43.5 million; ending cash balance: $556.1 million (including $230 million from July equity offering).
- Cost of goods sold: $1.1 million (low due to 0-cost inventory from pre-launch manufacturing).
- R&D expenses: $8.4 million (down 92% YoY due to reduced clinical trial activity post-approval).
- SG&A expenses: $33.8 million (up 25% YoY due to commercial launch investments).

**【Q&A Key Highlights】**
- **Discontinuation trends**: 8% AE-related discontinuations, with 10% total discontinuation rate. Anecdotal evidence shows patients restarting therapy after AE resolution.
- **Launch momentum**: Q3 start forms (+397) slower than Q2 (+646), but October activity similar to September, suggesting stabilization.
- **Payer access**: 132 million lives covered, including top 3 PBMs, with 40 state Medicaid programs reimbursing claims.
- **EU timeline**: No specific approval timeline, but regulatory process progressing with responses to EMA questions.
- **Competitor dynamics**: Rhythm's setmelanotide in PWS Phase II trial failed, but open-label data pending; potential for synergistic use with VYKAT XR if efficacy shown.

Soleno Therapeutics, Inc. (SLNO) Q3 2025 Earnings Call Transcript

- **Breakthrough Launch**: Vykat XR generated $32.7M in Q2, with 646 patient starts and 295 prescribers in first 3 months.
- **Rapid Payer Coverage**: 33% of U.S. insured lives (100M+) covered within 3 months, exceeding rare disease norms.
- **Strong Cash Position**: $523.8M post-Q2 financing ensures liquidity for U.S. launch and EU expansion.
- **Positive Safety & Compliance**: No new safety signals; discontinuation rates <12% vs. 15% in trials.
- **Global Expansion**: EU MAA validated; targeting ~9,000 PWS patients in Europe.

**【CEO Summary Section】**
- Launched Vykat XR in March 2025, generating $32.7 million in Q2 revenue, driven by 646 patient starts and 295 unique prescribers.
- Targeting EU expansion with MAA submission validated in May, addressing ~9,000 PWS patients in EU4 and UK.
- Emphasized strong cash position ($500M+ post-Q2 financing) to support U.S. launch and global expansion.

**【Chief Commercial Officer (Meredith Manning)】**
- 646 patient start forms received by Q2 end, with majority (>60%) aged 14-26 (vs. 13.5 avg. in trials).
- 295 unique prescribers, including >1/3 of top 300 PWS clinicians.
- 33% of U.S. insured lives (100M+) covered by Q2, with rapid payer policy approvals.

**【CFO Financial Commentary】**
- Q2 2025 net revenue: $32.7M (vs. $0 in Q2 2024).
- Operating cash outflow: $12.6M; ending cash: $293.8M + $230M equity raise = $523.8M.
- R&D expense: $9.1M (down 26% YoY); SG&A: $28.2M (up 164% YoY) due to launch investments.
- Net loss: $4.7M ($0.09/share) vs. $21.9M ($0.57/share) in Q2 2024.

**【Q&A Highlights】**
- July 2025 trends: Strong momentum continuing post-Q2, with no new safety signals.
- Time to fill: ~30 days target by steady state; currently 33% coverage → 100%+ over time.
- Compliance: Discontinuation rates < clinical trial rates (12% vs. 15% in Phase III).
- Europe strategy: Option to self-launch or partner, with ~$120-130M annual OpEx guidance for 2025.


Soleno Therapeutics, Inc. (SLNO) Q2 2025 Earnings Call Transcript

- **FDA Approval & Launch Success**: VYKAT XR approved in March 2025, with first patients treated 1 week ahead of schedule. 268 start forms received in 29 days.
- **Market Opportunity**: 10,000 addressable US patients; EU MAA submission planned for Q2 2025 targeting ~9,500 patients.
- **Financial Position**: $290M cash balance; $43.8M net loss in Q1 2025. $75M loan facility available post-approval.
- **Payer Progress**: 30+ states uploaded VYKAT XR into Medicaid; Soleno One program supports reimbursement challenges.
- **Global Expansion**: Evaluating self-commercialization vs. partnerships in Europe; competitive landscape includes Acadia and Arbor.

**【CEO Summary Section】**
- FDA approved VYKAT XR on March 26, 2025, for treating hyperphagia in PWS patients aged 4+ years. The drug was launched 1 week ahead of internal forecasts, with first patients treated by April 14.
- Addressable US market: ~10,000 patients (out of 12,000 diagnosed PWS individuals). No REMS program required; once-daily dosing with weight-based titration.
- Global expansion plans include EU MAA submission in Q2 2025, targeting ~9,500 PWS patients in the EU4+UK.

**【CFO Financial Commentary】**
- Q1 2025 cash balance: $290M (down from $318.6M at end of 2024). No revenue generated pre-launch; net loss of $43.8M ($0.95/share).
- R&D expenses: $13.5M (includes $4.3M non-cash stock comp). SG&A: $29.3M (includes $10.4M non-cash stock comp), up due to commercial readiness investments.
- $75M loan facility available post-approval, with two tranches over 18 months.

**【Commercial Progress (CCO)】**
- 268 patient start forms received in 29 days post-approval (April 14–May 7). 131 unique prescribers, including community physicians.
- Payer outreach: ~30 states have uploaded VYKAT XR into Medicaid systems. Soleno One program provides 24/7 patient support for reimbursement challenges.
- Early access programs: Bridge (clinical trial patients) and Quick Start (28-day supply for delayed reimbursement).

**【Q&A Highlights】**
- **Revenue Timing**: Specialty pharmacies are cautious on inventory build; modest Q2 revenue expected, with full launch execution lag (~6 months for payer policies).
- **Conversion Rate**: Comparable to other rare disease launches; unmet need suggests high conversion rates.
- **Europe Strategy**: MAA submission in Q2; evaluating self-commercialization vs. partnerships. EU PWS care similar to US, with centralized centers of excellence.
- **Competitors**: Acadia's carbetocin (Phase 3 with CRL) and Arbor's Phase 3 program are key late-stage threats.


Actual								-1.95	-2.4	-1.65	-0.6	-1.65	-2.1	-1.5	-0.6	-1.05	-0.9	-0.76	-0.58	-0.88	-0.81	-0.95	-0.33	-0.59	-0.57	-1.83	-1.27	-0.95	-0.09	0.47	0.8
Forecast								-3.075	-3.075	-1.3	-1.05	-1.15	-1.6	-1.65	-1.275	-1.05	-0.975	-0.91	-0.8	-0.725	-0.8267	-0.5767	-0.2733	-0.3671	-0.5671	-0.605	-0.9738	-0.97	-0.4533	0.0575	0.7108
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+36.59%	+21.95%	-26.92%	+42.86%	-43.48%	-31.25%	+9.09%	+52.94%	0.00%	+7.69%	+16.48%	+27.50%	-21.38%	+2.02%	-64.73%	-20.75%	-60.72%	-0.51%	-202.48%	-30.42%	+2.06%	+80.15%	+717.39%	+12.55%

Actual	--	--	--	--	--	--	--	--	--	0	0	0	0	0	--	--	--	--	--	0	0	0	0	0	0	0	0	0	32.66M	66.02M	91.73M
Forecast	--	--	--	--	--	--	--	0	0	0	0	0	0	0	0	--	--	--	--	--	0	0	0	0	0	0	0	0	25.14M	48.09M	88.75M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+29.92%	+37.27%	+3.36%

SLNO

SLNO fundamentals

SLNO Q4 2025 Earnings

Earnings Call

You can ask Aime

SLNO

SLNO fundamentals

SLNO Q4 2025 Earnings

Earnings Call

SLNO Earnings Call Summary for Q4/20254:30 PM on Feb 25, 2026

SLNO Earnings Call Summary for Q3/20254:30 PM on Nov 4, 2025

SLNO Earnings Call Summary for Q2/20254:30 PM on Aug 6, 2025

SLNO Earnings Call Summary for Q1/20254:30 PM on May 7, 2025

SLNO Earnings Call Summary for Q4/2024 Mar 28, 2026

You can ask Aime